IL22 and graft versus host disease: Interestingly, in vivo treatment of transplanted mice with the recombinant human IL-22 dimer/Fc fusion molecule F-652 (Generon Corp., Shanghai) reduced GVHD-related clinical scoring and mortality in a MHC-matched GVHD model76.